ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0783

Renal Dysfunction, COVID-19 Infection, and Mortality

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Olivera Arencibia, Yanetsy, Jackson Memorial Hospital, Miami, Florida, United States
  • Garcia Valencia, Oscar Alejandro, Jackson Memorial Hospital, Miami, Florida, United States
  • Salcedo Betancourt, Juan David, Jackson Memorial Hospital, Miami, Florida, United States
  • Contreras, Gabriel, Jackson Memorial Hospital, Miami, Florida, United States
  • Fornoni, Alessia, Jackson Memorial Hospital, Miami, Florida, United States
  • Taldone, Sabrina N., Jackson Memorial Hospital, Miami, Florida, United States
  • Patel, Sayari, University of Miami, Coral Gables, Florida, United States
  • Sands, Alexander R., University of Miami, Coral Gables, Florida, United States
  • Desir, Marie Claidee, University of Miami, Coral Gables, Florida, United States
  • Spring, Samantha, University of Miami, Coral Gables, Florida, United States
  • Marbin, Staci J., University of Miami, Coral Gables, Florida, United States
  • Shah, Anna K., University of Miami, Coral Gables, Florida, United States
  • Mcgaugh, Angela M., University of Miami, Coral Gables, Florida, United States
  • Sanon, Ciara Gwendoline, University of Miami, Coral Gables, Florida, United States
  • Wang, Jay-Shing, University of Miami, Coral Gables, Florida, United States
  • Baumrucker, Camille C., University of Miami, Coral Gables, Florida, United States
  • Patel, Nidhi, University of Miami, Coral Gables, Florida, United States
  • Greissman, Samantha R., University of Miami, Coral Gables, Florida, United States
  • Gulau, Matthew J., University of Miami, Coral Gables, Florida, United States
  • Dallera, Carlos Angel, University of Miami, Coral Gables, Florida, United States
  • Desai, Sohil S., University of Miami, Coral Gables, Florida, United States
  • Sosa, Marie A., Jackson Memorial Hospital, Miami, Florida, United States
Background

Critically ill patients with the SARS-CoV-2 virus (COVID-19) infection have diverse clinical manifestations including renal dysfunction which can determine their short-term outcomes. We assess if renal dysfunction on day one of hospital admission is associated with increased mortality risk of patients with severe COVID-19 infection.

Methods

We conducted a retrospective review of records of patients with severe COVID-19 infection admitted to the Intensive Care Unit between March 4 and April 11, 2020. Patients were divided into two groups based on serum creatinine level on day one of hospital admission. Group 1 included patients with normal serum creatinine (SCr) 1.10 mg/dl while group 2 included patients with high SCr > 1.10 mg/dl. The primary outcome was mortality. Secondary outcomes were the need for renal replacement therapy (RRT), duration of RRT, development of adult respiratory distress syndrome (ARDS) and need for mechanical ventilation. Comparisons between groups were done using Mann-Whitney U-tests for continuous variables and chi-square tests for categorical variables. Mortality was evaluated with a Kaplan-Meier Survival Analysis.

Results

A total of 47 patients were included: 27 in group 1 and 20 in group 2. Patients in group 2 compared to group 1 were older (67 vs. 56, p=0.04), more frequently African Americans (11% vs 45%, p=0.02), hypertensives (80% vs 52%, p=0.05) with chronic kidney disease (25% vs 0%, p=0.01), without significant differences sex, diabetes mellitus, smoking status or use of renin-angiotensin antagonists. 8 patients in group 2 and 3 patients in group 1 died, with significant difference in cumulative survival (Figure 1). Need for RRT (55% vs 41%, p=0.33), duration of RRT (6 vs 3 days, p=0.08), development of ARDS (85% vs 81%, p=0.75) and need for mechanical ventilation (65% vs 61%, p=0.89) were not significantly different between groups 2 and 1.

Conclusion

The presence of renal dysfunction on the day of hospital admission is associated with increased hospital mortality in patients with severe COVID-19 infection.

Funding

  • Other NIH Support